Harbour Investments’s Sarepta Therapeutics SRPT Stock Holding History

Harbour Investments’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.58K	Hold	422	–	–	﹤0.01%	3497
2026 Q1	$9.18K	Buy	422 +416	+6,933%	+$8.05K	﹤0.01%	3311
2025 Q4	$129	Hold	6	–	–	﹤0.01%	3720
2025 Q3	$116	Sell	6 -6	-50%	-$107	﹤0.01%	3631
2025 Q2	$205	Sell	12 -4	-25%	-$171	﹤0.01%	3471
2025 Q1	$1.02K	Buy	16 +8	+100%	+$842	﹤0.01%	3236
2024 Q4	$973	Sell	8 -4	-33%	-$490	﹤0.01%	3177
2024 Q3	$1.5K	Buy	12 +5	+71%	+$691	﹤0.01%	3009
2024 Q2	$1.11K	Hold	7	–	–	﹤0.01%	2977
2024 Q1	$906	Hold	7	–	–	﹤0.01%	2946
2023 Q4	$675	Sell	7 -13	-65%	-$1.25K	﹤0.01%	2883
2023 Q3	$2.42K	Buy	20 +14	+233%	+$1.58K	﹤0.01%	2500
2023 Q2	$687	Hold	6	–	–	﹤0.01%	2763
2023 Q1	$827	Hold	6	–	–	﹤0.01%	2719
2022 Q4	$777	Hold	6	–	–	﹤0.01%	2729
2022 Q3	$0	Hold	6	–	–	﹤0.01%	2826
2022 Q2	$0	Buy	+6	New	+$441	﹤0.01%	2826
2021 Q4	$1K	Sell	6 -116	-95%	-$9.92K	﹤0.01%	2560
2021 Q3	$11K	Sell	122 -137	-53%	-$10.6K	﹤0.01%	2625
2021 Q2	$20K	Sell	259 -2	-0.8%	-$152	﹤0.01%	2353
2021 Q1	$19K	Buy	+261	New	+$24.1K	﹤0.01%	2249

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Harbour Investments's SRPT Position: Q2 2026 in Review

Harbour Investments held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 422 shares worth $7.58K. The position accounts for ﹤0.01% of the portfolio, ranked #3497.

Harbour Investments first reported a position in SRPT in Q1 2021 and has held it in 21 quarters since. The position peaked at $20K in Q2 2021. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Harbour Investments held 422 shares of Sarepta Therapeutics worth $7.58K as of Q2 2026.
Harbour Investments left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #3497 holding.
Harbour Investments first reported a position in Sarepta Therapeutics in Q1 2021 and has held it in 21 quarters since.
Harbour Investments's Sarepta Therapeutics position peaked at $20K in Q2 2021.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.